Contact
searchSearch
HMP Global

Hidradenitis Suppurativa Topic Center

Featured

News
Emerging JAK1 and C5a Inhibitors Show Promise in Hidradenitis Suppurativa Network Meta-Analysis
03/31/2026
Riya Gandhi, MA
Comparative data highlight improved efficacy and tolerability signals with investigational therapies vs current standards.
Comparative data highlight improved efficacy and tolerability signals with investigational therapies vs current standards.
Comparative data highlight...
03/31/2026
The Dermatologist
News
Povorcitinib Demonstrates Meaningful Clinical Response in Anti-TNF–Experienced Hidradenitis Suppurativa Patients at 24 Weeks
03/31/2026
Riya Gandhi, MA
Phase 3 interim data show improved HiSCR responses and rapid pain reduction in a difficult-to-treat population.
Phase 3 interim data show improved HiSCR responses and rapid pain reduction in a difficult-to-treat population.
Phase 3 interim data show...
03/31/2026
The Dermatologist
HSF-Reviewed Content
From Reactive to Proactive: Building Longitudinal Care Plans That Actually Work for Hidradenitis Suppurativa
03/09/2026
Mondana Ghias, MD, FAAD
Through a longitudinal approach, care teams can achieve greater clarity, stability, and long-term disease control.
Through a longitudinal approach, care teams can achieve greater clarity, stability, and long-term disease control.
Through a longitudinal approach,...
03/09/2026
The Dermatologist
Gottlieb
Clinical Insights
Reimagining Hidradenitis Suppurativa Care: Early Recognition, Therapeutic Innovation, and Multidisciplinary Care Across the Patient Journey
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical and surgical management.
During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical and surgical management.
During an expert discussion,...
03/02/2026
The Dermatologist
Yoo
Clinical Insights
Ultrasound as a Transformative Tool in Dermatology: From Cosmetic Imaging to Hidradenitis Suppurativa Assessment and Emerging Therapies
03/02/2026
Hermon Feron, BA; Victoria Garfinkel, BSA
Dr Yoo and Dr Gottlieb reviewed the principles and applications of handheld ultrasound devices, sonographic assessment of hidradenitis suppurativa, aesthetic procedure guidance, and the expanding landscape of HS therapeutics.
Dr Yoo and Dr Gottlieb reviewed the principles and applications of handheld ultrasound devices, sonographic assessment of hidradenitis suppurativa, aesthetic procedure guidance, and the expanding landscape of HS therapeutics.
Dr Yoo and Dr Gottlieb reviewed...
03/02/2026
The Dermatologist
Face
FDA Alerts
Bimekizumab FDA Approved for Moderate to Severe Hidradenitis Suppurativa
11/20/2024
Riya Gandhi, MA
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug...
11/20/2024
The Dermatologist
Hidradenitis Suppurativa
News
Evolving Treatment Paradigms for Hidradenitis Suppurativa: The Role of Biologics
10/31/2024
Jessica Garlewicz
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS...
10/31/2024
The Dermatologist
FDA Alerts
Secukinumab Approved as New Biologic Treatment Option for Hidradenitis Suppurativa
11/01/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug...
11/01/2023
The Dermatologist
News
Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa
07/18/2023
Jessica Garlewicz
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a...
07/18/2023
The Dermatologist
News
Smoking and Obesity Are Important Research Questions for Managing Hidradenitis Suppurativa
04/10/2023
Lisa Kuhns, PhD, MD
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority...
04/10/2023
The Dermatologist
News
Complete Remission of Hidradenitis Suppurativa Reported After Treatment With Thoracodorsal Artery Perforator Flap
04/05/2023
Lisa Kuhns, PhD, MD
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator...
04/05/2023
The Dermatologist

Q&As

Q&As
Dr Amit Garg: Comorbidity Screening in HS
05/19/2021
Amit Garg, MD, shares insights into Hidradenitis Suppurativa and discusses his latest study, “Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations”.
Amit Garg, MD, shares insights into Hidradenitis Suppurativa and discusses his latest study, “Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations”.
Amit Garg, MD, shares insights...
05/19/2021
The Dermatologist
Q&As
Dr Haley Naik on Hidradenitis Suppurativa: Current Medical and Surgical Management
04/24/2021
Dr Haley Naik, MD, MHSc, FAAD joined The Dermatologist prior to her session at AAD VMX 2021 to discuss the current medical and surgical management options for hidradenitis suppurativa.
Dr Haley Naik, MD, MHSc, FAAD joined The Dermatologist prior to her session at AAD VMX 2021 to discuss the current medical and surgical management options for hidradenitis suppurativa.
Dr Haley Naik, MD, MHSc, FAAD...
04/24/2021
The Dermatologist
Q&As
The Who and When of Intralesional Injections for HS Treatment
03/26/2021
Steven R. Cohen, MD, MPH, met with The Dermatologist to discuss the efficacy of high dose intralesional triamcinolone (ILTAC) for hidradenitis suppurativa.
Steven R. Cohen, MD, MPH, met with The Dermatologist to discuss the efficacy of high dose intralesional triamcinolone (ILTAC) for hidradenitis suppurativa.
Steven R. Cohen, MD, MPH, met...
03/26/2021
The Dermatologist
Part 3
Q&As
Rebuilding Confidence in Alopecia Areata: Multidisciplinary, Holistic Support for Patients and Families
11/03/2025
Brittany Craiglow, MD; Brett A. King, MD, PhD; Maryanne Makredes Senna, MD
Experts explore holistic and emotional support strategies to empower patients with alopecia areata—beyond medicine, toward identity and healing.
Experts explore holistic and emotional support strategies to empower patients with alopecia areata—beyond medicine, toward identity and healing.
Experts explore holistic and...
11/03/2025
The Dermatologist
part 2
Q&As
Part 2: Advancing the Treatment Landscape in Severe Alopecia Areata
09/01/2025
Brittany Craiglow, MD; Brett A. King, MD, PhD; Maryanne Makredes Senna, MD
In Part 2 of this expert interview series, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna explore the latest treatment strategies for severe alopecia areata, including when to start JAK inhibitors, how to manage safety concerns,...
In Part 2 of this expert interview series, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna explore the latest treatment strategies for severe alopecia areata, including when to start JAK inhibitors, how to manage safety concerns,...
In Part 2 of this expert...
09/01/2025
The Dermatologist
Part 1 roundtable
Q&As
Part 1: Understanding the Emotional and Physical Toll of Alopecia Areata
08/04/2025
Brittany Craiglow, MD; Brett A. King, MD, PhD; Maryanne Makredes Senna, MD
In this candid and powerful conversation, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna share their clinical experiences treating patients with severe alopecia areata.
In this candid and powerful conversation, Dr Brittany Craiglow, Dr Brett King, and Dr Maryanne Senna share their clinical experiences treating patients with severe alopecia areata.
In this candid and powerful...
08/04/2025
The Dermatologist
Brandon Adler, MD
Q&As
Insights Into Photoprotection Updates
02/08/2024
Jessica Garlewicz
Dr Brandon Adler shared the latest updates in sunscreen usage, and how physicians can implement these changes in their practices.
Dr Brandon Adler shared the latest updates in sunscreen usage, and how physicians can implement these changes in their practices.
Dr Brandon Adler shared the...
02/08/2024
The Dermatologist
Glynis Ablon
Q&As
Enhancing Appearance Procedures
02/04/2024
Riya Gandhi, MA
In this interview, Dr Ablon explored cutting-edge techniques, personalized approaches, and practical insights in appearance procedures by addressing complications, patient satisfaction, and guidance for dermatologists.
In this interview, Dr Ablon explored cutting-edge techniques, personalized approaches, and practical insights in appearance procedures by addressing complications, patient satisfaction, and guidance for dermatologists.
In this interview, Dr Ablon...
02/04/2024
The Dermatologist
Jonathan Silverberg, MD, PhD, MPH
Q&As
Revolutionizing Atopic Dermatitis: Virtual Sessions on Optimizing Patient Care
12/13/2023
Jessica Garlewicz
Dr Jonathan Silverberg discussed how he hoped physicians gained a better understanding of the latest research and approaches when treating atopic dermatitis during the Revolutionizing Atopic Dermatitis virtual session.
Dr Jonathan Silverberg discussed how he hoped physicians gained a better understanding of the latest research and approaches when treating atopic dermatitis during the Revolutionizing Atopic Dermatitis virtual session.
Dr Jonathan Silverberg discussed...
12/13/2023
The Dermatologist
Elliott Campbell
Q&As
Gender Disparities and Advances in Cutaneous Melanoma
11/01/2023
Elliott Campbell, MD, FAAD
In this interview, Dr Elliott Campbell explores the increasing melanoma incidence among middle-aged women alongside stable rates in middle-aged men.
In this interview, Dr Elliott Campbell explores the increasing melanoma incidence among middle-aged women alongside stable rates in middle-aged men.
In this interview, Dr Elliott...
11/01/2023
The Dermatologist
Ilka A. Netravali, MD, PhD, FAAD
Q&As
Rapid Resolution of Diffuse Warts Following Initiation of Dupilumab for Severe Atopic Dermatitis
10/30/2023
Ilka Arun Netravali, MD, PhD, FAAD
Dr Ilka Netravali shared insights from her study, “Rapid Resolution of Diffuse Warts Following Initiation of Dupilumab for Severe Atopic Dermatitis.”
Dr Ilka Netravali shared insights from her study, “Rapid Resolution of Diffuse Warts Following Initiation of Dupilumab for Severe Atopic Dermatitis.”
Dr Ilka Netravali shared...
10/30/2023
The Dermatologist
Jeremy Etzkorn-2019
Q&As
Nasal Function and Appearance Post Flap Repair: NAFEQ Study
09/26/2023
Jeremy Etzkorn, MD; Nicholas J. Golda, MD
In this interview, Dr Etzkorn and Dr Golda discussed the findings of their multi-center prospective cohort study on patients undergoing 2-stage interpolated flap repair for nasal defects.
In this interview, Dr Etzkorn and Dr Golda discussed the findings of their multi-center prospective cohort study on patients undergoing 2-stage interpolated flap repair for nasal defects.
In this interview, Dr Etzkorn...
09/26/2023
The Dermatologist
Steven Feldman
Q&As
Advancing Psoriasis Patient Care
09/25/2023
Steven R. Feldman, MD, PhD
In this interview with The Dermatologist, Dr Steven Feldman discusses his session, “Better Care for Psoriasis Patients,” presented at Fall Dermatology Week 2023.
In this interview with The Dermatologist, Dr Steven Feldman discusses his session, “Better Care for Psoriasis Patients,” presented at Fall Dermatology Week 2023.
In this interview with The...
09/25/2023
The Dermatologist

Multimedia

Dr Sherry Yang
Videos
Inflammation's Role in the Disease Progression of HS
11/17/2021
Sherry Yang, MD, FAAD
Dr Sherry Yang discusses the various causes of inflammation and their role in the disease progression of patients with HS.
Dr Sherry Yang discusses the various causes of inflammation and their role in the disease progression of patients with HS.
Dr Sherry Yang discusses the...
11/17/2021
The Dermatologist
Dr Sherry Yang
Videos
Demographics & Characteristics Associated With HS Diagnoses
11/12/2021
Sherry Yang, MD, FAAD
Dr Sherry Yang discusses patient demographics and characteristics that are associated with HS diagnoses.
Dr Sherry Yang discusses patient demographics and characteristics that are associated with HS diagnoses.
Dr Sherry Yang discusses patient...
11/12/2021
The Dermatologist
Dr Sherry Yang
Videos
How to Approach HS Treatment
11/05/2021
Sherry Yang, MD, FAAD
Dr Sherry Yang discusses how individualizing treatment plans for each patient is one of the best approaches to combatting HS symptoms.
Dr Sherry Yang discusses how individualizing treatment plans for each patient is one of the best approaches to combatting HS symptoms.
Dr Sherry Yang discusses how...
11/05/2021
The Dermatologist
Videos
Clinical Implications of HS and Hepatitis B/C
06/10/2021
Dr Cohen shares the clinical implications of hepatitis B and hepatitis C in patients with HS in this 8-minute video.
Dr Cohen shares the clinical implications of hepatitis B and hepatitis C in patients with HS in this 8-minute video.
Dr Cohen shares the clinical...
06/10/2021
The Dermatologist
Videos
Genetic Components and Hepatitis Risks in HS
06/10/2021
In this video interview, Dr Cohen highlights results of his recent study into HS and hepatitis B and C.
In this video interview, Dr Cohen highlights results of his recent study into HS and hepatitis B and C.
In this video interview, Dr...
06/10/2021
The Dermatologist
Podcasts
Updates in HS: Dr Rosenblum on Pathophysiology
12/15/2020
In this podcast, Michael Rosenblum, MD, reviews the pathophysiology of hidradenitis suppurativa and a possible immune activation signature that could potentially identify patients who may respond to TNF therapies.
In this podcast, Michael Rosenblum, MD, reviews the pathophysiology of hidradenitis suppurativa and a possible immune activation signature that could potentially identify patients who may respond to TNF therapies.
In this podcast, Michael...
12/15/2020
The Dermatologist
Podcasts
Dr Iltefat Hamzavi on Managing Hidradenitis Suppurativa
09/16/2020
In this podcast, Iltefat Hamzavi, MD, discusses therapeutic options for managing flares, the role of lasers, and new therapies in the pipeline for hidradenitis suppurativa.
In this podcast, Iltefat Hamzavi, MD, discusses therapeutic options for managing flares, the role of lasers, and new therapies in the pipeline for hidradenitis suppurativa.
In this podcast, Iltefat...
09/16/2020
The Dermatologist
Heberton
Videos
Managing EGFR Skin Toxicities
04/01/2026
Riya Gandhi, MA
This interview focuses on the most common EGFR inhibitor–associated skin adverse events, when they typically emerge, and practical strategies to reduce severity—including skincare routines, photoprotection, and prophylactic approaches.
This interview focuses on the most common EGFR inhibitor–associated skin adverse events, when they typically emerge, and practical strategies to reduce severity—including skincare routines, photoprotection, and prophylactic approaches.
This interview focuses on the...
04/01/2026
The Dermatologist
Amy paller
Videos
Disease Biology and Early Recognition in Atopic Dermatitis
04/01/2026
Amy S. Paller, MD, MS; Riya Gandhi, MA
Dr Amy Paller discusses how recognizing pediatric atopic dermatitis as a type 2 inflammatory disease has transformed early treatment strategies, enabling safer and more proactive use of targeted therapies.
Dr Amy Paller discusses how recognizing pediatric atopic dermatitis as a type 2 inflammatory disease has transformed early treatment strategies, enabling safer and more proactive use of targeted therapies.
Dr Amy Paller discusses how...
04/01/2026
The Dermatologist
Joseph F. Merola, MD, MMSc, and Colby Evans, MD
Videos
Autoimmune Serologies in Dermatology
04/01/2026
Riya Gandhi, MA
Dr Joseph Merola breaks down how dermatologists can accurately interpret autoimmune serologies, with a focus on ANA testing, clinical context, and avoiding unnecessary labs.
Dr Joseph Merola breaks down how dermatologists can accurately interpret autoimmune serologies, with a focus on ANA testing, clinical context, and avoiding unnecessary labs.
Dr Joseph Merola breaks down how...
04/01/2026
The Dermatologist
Melissa Mauskar, MD
Videos
Practical Pearls of Vulvar Dermatoses
04/01/2026
Riya Gandhi, MA
Dr Melissa Mauskar discusses common diagnostic pitfalls in vulvar dermatoses, including overlapping conditions and misdiagnosis of lichen sclerosus versus genitourinary syndrome of menopause.
Dr Melissa Mauskar discusses common diagnostic pitfalls in vulvar dermatoses, including overlapping conditions and misdiagnosis of lichen sclerosus versus genitourinary syndrome of menopause.
Dr Melissa Mauskar discusses...
04/01/2026
The Dermatologist
Guttman
Videos
Chronic Hand Eczema: Pathways and Emerging Therapies
04/01/2026
Riya Gandhi, MA
Dr Emma Guttman explains how chronic hand eczema is now understood as a heterogeneous disease driven by different immune pathways depending on underlying causes.
Dr Emma Guttman explains how chronic hand eczema is now understood as a heterogeneous disease driven by different immune pathways depending on underlying causes.
Dr Emma Guttman explains how...
04/01/2026
The Dermatologist
Elman
Videos
Baseline Screening and Monitoring for Biologics and Small Molecules
04/01/2026
Scott Andrew Elman, MD, FAAD; Riya Gandhi, MA
Are dermatologists overtesting patients on biologics and new oral therapies? Dr Scott Elman explains how mechanism-based screening can reduce unnecessary testing while maintaining patient safety.
Are dermatologists overtesting patients on biologics and new oral therapies? Dr Scott Elman explains how mechanism-based screening can reduce unnecessary testing while maintaining patient safety.
Are dermatologists overtesting...
04/01/2026
The Dermatologist
brad glick
Videos
Oral Therapies in Psoriasis
04/01/2026
Riya Gandhi, MA
Dr Brad Glick discusses persistent unmet needs in psoriasis care, including undertreatment, low systemic therapy adoption, and challenges in high-impact disease areas.
Dr Brad Glick discusses persistent unmet needs in psoriasis care, including undertreatment, low systemic therapy adoption, and challenges in high-impact disease areas.
Dr Brad Glick discusses...
04/01/2026
The Dermatologist
Videos
Hidradenitis Suppurativa: Early Recognition, IL-17 Targeted Therapies, and Multidisciplinary Care
04/01/2026
Riya Gandhi, MA
Dr Jack O’Brien discusses how dermatologists can reduce diagnostic delays in hidradenitis suppurativa by recognizing early clinical signs such as recurrent abscesses in intertriginous areas and associated acne.
Dr Jack O’Brien discusses how dermatologists can reduce diagnostic delays in hidradenitis suppurativa by recognizing early clinical signs such as recurrent abscesses in intertriginous areas and associated acne.
Dr Jack O’Brien discusses how...
04/01/2026
The Dermatologist
Asempa
Videos
Improving Dermatology Measures for Skin of Color and Underrepresented Groups
04/01/2026
Riya Gandhi, MA
This interview examines the limitations of commonly used dermatology outcome measures in patients with skin of color and other underrepresented populations.
This interview examines the limitations of commonly used dermatology outcome measures in patients with skin of color and other underrepresented populations.
This interview examines the...
04/01/2026
The Dermatologist
Orgill
Videos
Mohs Reconstruction Collaboration
04/01/2026
Riya Gandhi, MA
Dr Dennis Orgill discusses when dermatologists should involve plastic surgeons after Mohs surgery, particularly for complex defects in high-visibility areas such as the nose, eyes, and mouth.
Dr Dennis Orgill discusses when dermatologists should involve plastic surgeons after Mohs surgery, particularly for complex defects in high-visibility areas such as the nose, eyes, and mouth.
Dr Dennis Orgill discusses when...
04/01/2026
The Dermatologist

Quizzes

severe hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa Risk Factor for Infection Following Procedures
07/26/2022
Jessica Garlewicz
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following...
07/26/2022
The Dermatologist
hidradenitis suppurativa under arm
Quiz
Trivia: Internalized Skin Bias in HS
05/17/2022
Jessica Garlewicz
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options...
05/17/2022
The Dermatologist
HS lesions
Quiz
Trivia: Are Female Patients With HS At High Risk for Adverse Pregnancy Outcomes?
12/21/2021
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: How are Patients With HS and Hepatitis B or C Systemically Treated?
12/21/2021
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: What is the Optimal Dose Regimen Recommended for HS Lesions?
12/21/2021
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of...
12/21/2021
The Dermatologist
hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa and the Risk for Hepatitis B and C
12/20/2021
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with...
12/20/2021
The Dermatologist
hidradenitis in armpit
Quiz
Trivia: Characteristics Tied to New Hidradenitis Suppurativa Diagnoses
12/17/2021
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD,...
12/17/2021
The Dermatologist
hidradenitis
Quiz
Trivia: Risk for Therapy Discontinuation Among Patients With HS
12/10/2021
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of...
12/10/2021
The Dermatologist
hidradenitis tunneling
Quiz
Trivia: Ranking of Monotherapies for Hidradenitis Suppurativa
12/03/2021
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the...
12/03/2021
The Dermatologist
Hidradenitis Suppurativa, as shown here, is a terrible condition that can affect pediatric patients and their HS treatment.
Quiz
Trivia: Physical and Psychosocial Comorbidities in Pediatric HS
09/28/2021
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these...
09/28/2021
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist
psoriasis
Quiz
Quiz: Misdiagnosis of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized...
03/02/2026
The Dermatologist
Quiz
Allergic Disease Progression: Genetics and Environment
02/26/2026
Riya Gandhi, MA
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between...
02/26/2026
The Dermatologist
Quiz
Early Intervention Strategies in Pediatric Atopic Dermatitis
02/26/2026
Riya Gandhi, MA
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of...
02/26/2026
The Dermatologist
Quiz
Air Pollution and Atopic Disease: Evaluating Epidemiologic Evidence
02/26/2026
Riya Gandhi, MA
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the...
02/26/2026
The Dermatologist

News

Face
FDA Alerts
Bimekizumab FDA Approved for Moderate to Severe Hidradenitis Suppurativa
11/20/2024
Riya Gandhi, MA
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug...
11/20/2024
The Dermatologist
Hidradenitis Suppurativa
News
Evolving Treatment Paradigms for Hidradenitis Suppurativa: The Role of Biologics
10/31/2024
Jessica Garlewicz
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS includes both topical and systemic medications, as well as a variety of surgical interventions.
Currently, treatment for HS...
10/31/2024
The Dermatologist
FDA Alerts
Secukinumab Approved as New Biologic Treatment Option for Hidradenitis Suppurativa
11/01/2023
Jessica Garlewicz
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug...
11/01/2023
The Dermatologist
News
Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa
07/18/2023
Jessica Garlewicz
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a retrospective analysis and patient surveys to investigate the efficacy and patient experience of intramuscular triamcinolone therapy for acute, severe hidradenitis suppurativa flares.
Researchers aimed to conduct a...
07/18/2023
The Dermatologist
News
Smoking and Obesity Are Important Research Questions for Managing Hidradenitis Suppurativa
04/10/2023
Lisa Kuhns, PhD, MD
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa (HS) was developed in a recent Delphi consensus study.
An expert consensus of priority...
04/10/2023
The Dermatologist
News
Complete Remission of Hidradenitis Suppurativa Reported After Treatment With Thoracodorsal Artery Perforator Flap
04/05/2023
Lisa Kuhns, PhD, MD
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator (TDAP) flap-based reconstruction following wide local excision (WLE) resulted in the complete remission of hidradenitis suppurativa (HS), according to a recent study published in Plastic and Reconstructive...
Thoracodorsal artery perforator...
04/05/2023
The Dermatologist
News
Effectiveness and Pain Reduction Identified as the Most Important Treatment Attributes in Hidradenitis Suppurativa Management
01/31/2023
Lisa Kuhns, PhD, MD
In a multinational discrete choice experiment, researchers aimed to determine which treatment attributes adult patients with HS in Europe consider the most important in treatment decision-making.
In a multinational discrete choice experiment, researchers aimed to determine which treatment attributes adult patients with HS in Europe consider the most important in treatment decision-making.
In a multinational discrete...
01/31/2023
The Dermatologist
News
Hidradenitis Suppurativa Contributes to Relationship Disturbances
12/08/2022
Lisa Kuhns, PhD, MD
Researchers aimed to determine relationship disturbances in HS using an anonymous electronic survey.
Researchers aimed to determine relationship disturbances in HS using an anonymous electronic survey.
Researchers aimed to determine...
12/08/2022
The Dermatologist
News
Pediatric Hidradenitis Suppurativa Presents Similar Clinical Spectrum to Adult-Onset Disease
11/30/2022
Lisa Kuhns, PhD, MD
Researchers performed a cross-sectional study on the clinical features and treatment approaches of pediatric HS.
Researchers performed a cross-sectional study on the clinical features and treatment approaches of pediatric HS.
Researchers performed a...
11/30/2022
The Dermatologist
News
Stigmatization Has a Debilitating Impact on Patients With Hidradenitis Suppurativa
11/18/2022
Lisa Kuhns, PhD, MD
Researchers performed an observational study that aimed to assess how feelings of stigmatization may relate to patient quality of life, depression, and social anxiety.
Researchers performed an observational study that aimed to assess how feelings of stigmatization may relate to patient quality of life, depression, and social anxiety.
Researchers performed an...
11/18/2022
The Dermatologist
psoriasis0
News
Altered Lysine Crotonylation Identified in Psoriatic Skin
03/19/2026
Jessica Garlewicz
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a post-translational modification previously studied in oncology, may play a role in psoriasis pathogenesis, according to a translational study comparing protein modification profiles in lesional and non-lesional skin.
Lysine crotonylation, a...
03/19/2026
The Dermatologist
FDA Alerts
FDA Approves Icotyde (icotrokinra) for the Treatment of Moderate-To-Severe Plaque Psoriasis in Adults and Pediatric Patients
03/18/2026
Jessica Garlewicz
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug...
03/18/2026
The Dermatologist
FDA Alerts
FDA Approves Cosentyx for the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate-To-Severe Hidradenitis Suppurativa
03/17/2026
Jessica Garlewicz
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug...
03/17/2026
The Dermatologist
atopic dermatitis
News
Mixed Associations Between Socioeconomic Status and Pediatric Atopic Dermatitis Highlight Research Gaps
03/11/2026
Jessica Garlewicz
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to influence pediatric atopic dermatitis, but the direction and strength of the association remain unclear.
Socioeconomic status appears to...
03/11/2026
The Dermatologist
FDA Alerts
FDA Approves Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis
03/10/2026
Jessica Garlewicz
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food...
03/10/2026
The Dermatologist
psoriasis
News
Biologic Therapy Improves Psychological Well-Being and Quality of Life in Psoriasis
03/03/2026
Jessica Garlewicz
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for moderate-to-severe plaque psoriasis was associated with marked improvements in psychological distress and quality of life in a real-world clinical setting.
Biologic therapy for...
03/03/2026
The Dermatologist
psoriasis
News
Low Prevalence but Meaningful Impact of Psychological Symptoms Seen in Well-Controlled Psoriasis
02/03/2026
Jessica Garlewicz
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms can still occur in young adults with well-controlled psoriasis, even when disease activity is minimal, according to a cross-sectional study exploring psychological distress and its potential biological...
Anxiety and depression symptoms...
02/03/2026
The Dermatologist
psoriasis
News
Mathematical Modeling Study Highlights Cytokine Balance and Stem Cell Feedback in Psoriasis Control
01/22/2026
Jessica Garlewicz
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study using mathematical modeling provides insight into how cytokine imbalance drives psoriasis flares and suggests that restoring immune-epidermal feedback.
A new systems biology study...
01/22/2026
The Dermatologist
Cutaneous Squamous Cell Carcinoma
News
Managing Cutaneous Squamous Cell Carcinoma
01/06/2026
Jessica Garlewicz
An updated evidence-based review outlines contemporary strategies for evaluating and managing cutaneous squamous cell carcinoma.
An updated evidence-based review outlines contemporary strategies for evaluating and managing cutaneous squamous cell carcinoma.
An updated evidence-based review...
01/06/2026
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5
10/06/2025
Riya Gandhi, MA
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA...
10/06/2025
The Dermatologist

Popular Articles

Atopic dermatitis
Quiz
Quiz: Atopic Dermatitis Spotlight
05/06/2024
Riya Gandhi, MA
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications...
05/06/2024
The Dermatologist
Hausauer
Conference Coverage
Exploring Platelet-Rich Plasma in Dermatology
05/11/2024
Riya Gandhi, MA
In her session, “Platelet-Rich Plasma in Dermatology,” presented at Spring Dermatology Week 2024, Dr Amelia Hausauer illuminated the landscape of platelet-rich plasma in dermatology.
In her session, “Platelet-Rich Plasma in Dermatology,” presented at Spring Dermatology Week 2024, Dr Amelia Hausauer illuminated the landscape of platelet-rich plasma in dermatology.
In her session, “Platelet-Rich...
05/11/2024
The Dermatologist
AD
News
Efficacy of Targeted Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis
06/15/2024
Riya Gandhi, MA
A recent study, published in SKIN The Journal of Cutaneous Medicine, has compared the efficacy of various targeted systemic monotherapies for moderate-to-severe atopic dermatitis, including the emerging biologic lebrikizumab.
A recent study, published in SKIN The Journal of Cutaneous Medicine, has compared the efficacy of various targeted systemic monotherapies for moderate-to-severe atopic dermatitis, including the emerging biologic lebrikizumab.
A recent study, published in...
06/15/2024
The Dermatologist
NRS Approved Features
Establishing a Core Domain Set for Rosacea Clinical Trials
08/05/2024
Riya Gandhi, MA
A recent consensus statement addresses the need for standardized outcome measures in clinical trials involving patients with rosacea.
A recent consensus statement addresses the need for standardized outcome measures in clinical trials involving patients with rosacea.
A recent consensus statement...
08/05/2024
The Dermatologist
acne
News
Therapeutic Relevance of Sebum in the Pathophysiology of Acne Vulgaris
09/19/2024
Jessica Garlewicz
Sebum production and its role in the pathophysiology of acne vulgaris have been long debated.
Sebum production and its role in the pathophysiology of acne vulgaris have been long debated.
Sebum production and its role in...
09/19/2024
The Dermatologist
cover March 2026

Current Issue

March 2026
Volume 34
Issue 2
Current Issue
Issue Archive

Latest Quizzes and Trivia

severe hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa Risk Factor for Infection Following Procedures
07/26/2022
Jessica Garlewicz
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following procedures have a heightened risk of infection in hidradenitis suppurativa skin lesions? Take the quiz!
Which of the following...
07/26/2022
The Dermatologist
hidradenitis suppurativa under arm
Quiz
Trivia: Internalized Skin Bias in HS
05/17/2022
Jessica Garlewicz
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options are predictors of impaired health-related quality of life?
Which of the following options...
05/17/2022
The Dermatologist
HS lesions
Quiz
Trivia: Are Female Patients With HS At High Risk for Adverse Pregnancy Outcomes?
12/21/2021
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an independent risk factor for adverse pregnancy and maternal outcomes.
True or false: HS is an...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: How are Patients With HS and Hepatitis B or C Systemically Treated?
12/21/2021
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS who have hepatitis B or C are always given the same standard treatment.
True or false: Patients with HS...
12/21/2021
The Dermatologist
HS lesions
Quiz
Trivia: What is the Optimal Dose Regimen Recommended for HS Lesions?
12/21/2021
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of intralesional steroids is very ineffective with traditional doses of 5 mg/mL and 10 mg/mL.
True or false: The use of...
12/21/2021
The Dermatologist
hidradenitis suppurativa
Quiz
Trivia: Hidradenitis Suppurativa and the Risk for Hepatitis B and C
12/20/2021
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with hidradenitis suppurativa are at an increased risk for hepatitis B or C.
True or False: Patients with...
12/20/2021
The Dermatologist
hidradenitis in armpit
Quiz
Trivia: Characteristics Tied to New Hidradenitis Suppurativa Diagnoses
12/17/2021
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD, FAAD, which characteristics are associated with new HS diagnoses?
According to Sherry Yang, MD,...
12/17/2021
The Dermatologist
hidradenitis
Quiz
Trivia: Risk for Therapy Discontinuation Among Patients With HS
12/10/2021
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of patients with hidradenitis suppurativa, the risk for discontinuation of was significantly lower among those given etanercept vs adalimumab, infliximab, and ustekinumab.
True or False: In a study of...
12/10/2021
The Dermatologist
hidradenitis tunneling
Quiz
Trivia: Ranking of Monotherapies for Hidradenitis Suppurativa
12/03/2021
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the efficacy of single-agent therapies for patients with HS.
Test your knowledge of the...
12/03/2021
The Dermatologist
Hidradenitis Suppurativa, as shown here, is a terrible condition that can affect pediatric patients and their HS treatment.
Quiz
Trivia: Physical and Psychosocial Comorbidities in Pediatric HS
09/28/2021
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these options lists some of the comorbidities associated with pediatric with HS?
Can you identify which of these...
09/28/2021
The Dermatologist
Quiz
Type 2 Inflammation and Early Systemic Therapy in Pediatric Atopic Dermatitis
04/05/2026
Riya Gandhi, MA
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical...
04/05/2026
The Dermatologist
Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist
psoriasis
Quiz
Quiz: Misdiagnosis of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized...
03/02/2026
The Dermatologist
Quiz
Allergic Disease Progression: Genetics and Environment
02/26/2026
Riya Gandhi, MA
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between...
02/26/2026
The Dermatologist
Quiz
Early Intervention Strategies in Pediatric Atopic Dermatitis
02/26/2026
Riya Gandhi, MA
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of...
02/26/2026
The Dermatologist
Quiz
Air Pollution and Atopic Disease: Evaluating Epidemiologic Evidence
02/26/2026
Riya Gandhi, MA
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the...
02/26/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use